5-amino-1mq

5-Amino-1-methylquinolinium is a small-molecule cationic heterocycle whose quinolinium scaffold provides the structural basis for NNMT-active-site engagement documented in the published literature. The compound's interaction profile centers on competitive inhibition at the NNMT methyl-acceptor site, with reported selectivity over related methyltransferases in published in-vitro screens. Pharmacokinetic descriptors documented in published animal-model investigations include rapid absorption following oral paradigms in rodent studies and moderate plasma residence under standard parenteral routes. Interaction profile in the literature spans NNMT competitive inhibition, downstream effects on cellular NAD+ and 1-methylnicotinamide levels in cell-culture investigations, and metabolic-pathway research in adipose-tissue and skeletal-muscle cell models. All activity descriptors here are framed as documented in published research. Structural confirmation of supplied lots is established by mass spectrometry molecular-ion match and HPLC-validated purity reported on each Certificate of Analysis.

Experimental domains documented in the published literature include NNMT enzyme-inhibition kinetic studies, structure-activity investigations probing the role of the 5-amino substituent in active-site engagement, cellular NAD+ and 1-methylnicotinamide level analysis in cell-culture systems, metabolic-pathway research in adipocyte and skeletal-muscle-cell models, and comparative work alongside other NNMT inhibitor scaffolds. Investigators have also characterized 5-Amino-1MQ in screening assays for methyltransferase-selective inhibitor discovery and in studies probing the role of NNMT in cellular methylation-pathway flux. Use in laboratory research extends to mechanism-elucidation paradigms where the small molecule serves as a defined NNMT-inhibitor reference. The reference material is supplied for these and equivalent in-vitro and animal-model experimental contexts only, with no associated guidance for human, clinical, or veterinary application.

Each lot is characterized by reverse-phase HPLC for chromatographic purity and by mass spectrometry for molecular-ion confirmation against the C10H11N2+ empirical formula. Purity is reported as an HPLC-area percentage on the Certificate of Analysis distributed with every lot, alongside the molecular-weight match within instrument tolerance. Counter-ion identity (typically iodide for the methylquinolinium salt form) is confirmed when included in the lot's release specification. Residual solvent and water content are reported categorically when these parameters are part of the lot's release specification. The COA records the lot identifier, manufacturing date, and analytical method versions used, providing a traceable provenance chain from synthesis through release. Researchers requiring batch-level analytical detail should reference the COA distributed with the supplied material rather than rely on category-level summaries.

For laboratory storage, the small-molecule reference standard should be held in its sealed, light-protected container at the temperature specified on the product label (typically 2–8°C or −20°C depending on the salt form and packaging). Allow vials to equilibrate to ambient temperature before opening to avoid moisture condensation. Reconstitution for in-vitro experimental use is typically performed in DMSO, water, or a researcher-selected solvent compatible with the downstream enzyme-assay buffer; once reconstituted, store the working solution at 2–8°C and characterize stability in the relevant solvent prior to extended storage. Quinolinium salts can be photosensitive — minimize prolonged light exposure of stock solutions. Avoid repeated freeze-thaw cycles. These handling parameters reflect general best-practice for small-molecule research standards and do not constitute preparation guidance for human or veterinary application.